Sempere Verdú Ermengol, Salazar Fraile José, Palop Larrea Vicente, Vicens Caldentey Caterina
Médico de familia, Centro de Salud de Paterna, Paterna, Valencia, España.
Psiquiatra, Centro de Salud de Paterna, Paterna, Valencia, España.
Aten Primaria. 2014 Oct;46(8):416-25. doi: 10.1016/j.aprim.2013.11.006. Epub 2014 Feb 18.
To describe the evolution in the use of antidepressants (AD), anxiolytics (A) and hypnotics (H) in the Comunitat Valenciana (CV) between 2000 and 2010, their expenditure, and the cost of the defined daily dose (DDD).
Retrospective observational study.
Prescriptions covered by the health public service of the CV during the period 2000-2010.
Consumption of the therapeutic groups N06A (antidepressants), N05B (anxiolytics) and N05C (hypnotics) from the pharmacy database of the public Valencian Health Agency measured in defined daily dose per 1.000 inhabitants.
During the period of study the use of AD increased by 81.2% and A and H, 11.7%. Selective serotonin reuptake inhibitors were the most prescribed AD and Selective serotonin and norepinephrine reuptake inhibitors experienced the higher rise (386.8%). The increase of escitalopram was 1.013%. Lorazepam, alprazolam and diazepam, accounted for the 80.4% of the anxyolitics, and lormetazepam and zolpidem the 88.7% of the hypnotics. The expenditure rise of AD was by 78.2% and that of the A and H was 14.5%; the cost of the DDD of both decreased by 29%.
Antidepressant utilization has experienced a remarkable rise between 2000 and 2010 while that of A and H has been mild even though they are still more consumed than AD. In spite of the reduction of the DDD cost in both therapeutic groups, the whole expenditure on AD in the CV is still growing.
描述2000年至2010年间瓦伦西亚自治区(CV)抗抑郁药(AD)、抗焦虑药(A)和催眠药(H)的使用演变、其支出以及限定日剂量(DDD)成本。
回顾性观察研究。
2000 - 2010年期间CV公共卫生服务涵盖的处方。
从瓦伦西亚公共卫生机构药房数据库中获取治疗组N06A(抗抑郁药)、N05B(抗焦虑药)和N05C(催眠药)的消费量,以每1000居民的限定日剂量衡量。
在研究期间,AD的使用增加了81.2%,A和H增加了11.7%。选择性5-羟色胺再摄取抑制剂是处方最多的AD,选择性5-羟色胺和去甲肾上腺素再摄取抑制剂增长幅度最大(386.8%)。艾司西酞普兰的增幅为1013%。劳拉西泮、阿普唑仑和地西泮占抗焦虑药的80.4%,氯美扎酮和唑吡坦占催眠药的88.7%。AD的支出增长了78.2%,A和H的支出增长了14.5%;两者的DDD成本均下降了29%。
2000年至2010年间抗抑郁药的使用显著增加,而A和H的使用虽增幅较小,但仍比AD的消费量更大。尽管两个治疗组的DDD成本都有所降低,但CV中AD的总支出仍在增长。